| Date | Title | Description |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 06.08.2024 | Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights | Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor
Initiated global clinical trial collaboration with Pfizer for combinat... |
| 22.02.2024 | Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights | Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg
Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-... |
| 08.01.2024 | Relay Therapeutics Announces $30 Million Private Placement Financing | CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental techno... |
| 08.01.2024 | Relay Therapeutics Announces $30 Million Private Placement Financing | - |
| 04.05.2023 | Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights | /EIN News/ -- Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023
Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor
$937.8 million in cash... |
| 13.04.2023 | Conga Announces Winners of 2023 Inspire Awards at Annual Conga Connect Conference | The quality of this year’s customer nominations is a true testament to the power and impact that Revenue Lifecycle Management can have on the success of business overall. We are beyond proud to be able to partner with these customers to hel... |
| 10.12.2021 | Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination | CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental techno... |
| 08.10.2021 | Relay Therapeutics : Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor | Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)
RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR t... |
| 08.10.2021 | Relay Therapeutics : Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα - Form 8-K | Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα
RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platfo... |
| 07.10.2021 | Relay Therapeutics : Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα | RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform
Preclinically, achieved tumor regressions in vivo with significantly reduced impact on glucose metabolism compared to active site inhib... |
| 16.04.2021 | RELAY THERAPEUTICS, INC.
Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI | Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields
ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library o... |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages
The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 16.07.2020 | Relay Therapeutics prices IPO at $400M | Relay initially filed to go public with the Securities and Exchange Commission on June 25, stating that it was looking to raise $200 million. It had completed a Series C venture capital funding round worth $400 million in December 2018. Sin... |
| 10.07.2020 | Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO | Relay Therapeutics, a Cambridge, Mass.-biotech focusing on cancer treatments, plans to raise $250 million when it goes public, amid strong recent stock market debuts by other biopharma startups.
The startup is developing treatments for soli... |
| 25.06.2020 | Protein motion-focused Relay Therapeutics files for $200M IPO | While targeted drugs often work by preventing the binding of a ligand to its active site, Relay’s allosteric drug-discovery approach involves the combination of structural biology, biophysics, computational technology and research from othe... |
| 27.12.2018 | Relay Therapeutics Lands $400M Series C |
CAMBRIDGE, MA, Relay Therapeutics announced the successful completion of a $400 million Series C financing.
>> Click here for more funding data on Relay Therapeutics
>> To export Relay Therapeutics funding data to PDF and Ex... |
| 20.12.2018 | Biotech startup Relay Therapeutics raises $400 million from SoftBank, GV, others | Relay Therapeutics, a biotechnology startup that’s meshing computational power with the latest experimental techniques around “protein motion” to create a cutting-edge drug discovery engine, has raised a whopping $400 million in a series C ... |
| 20.12.2018 | Daily funding roundup - December 20th, 2018 | Layer1 raised $2.1M; Gamelearn raised $5M; BacklotCars raised $8; DrChrono raised $10M
Layer1: Layer1 is a cryptoasset investment and infrastructure platform. One months-old, San Francisco-based company has raised $2.1 million in funding fr... |
| 20.12.2018 | Relay Therapeutics hits VC jackpot with $400M Series C round for protein motion drug discovery | The company’s Series B financing was completed on Dec. 14, 2017 and valued at $63 million. BVF Partners led the round, with participation from GV, Casdin Capital, EcoR1 Capital and Section 32. Prior to Wednesday, the company had raised $120... |
| 20.12.2018 | Relay Therapeutics Secures $400 Million in Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced the successful completion of a $400 million Series C financing.
Relay Therapeutics combines ... |
| 20.12.2018 | Biotech startup Relay Therapeutics raises $400 million from SoftBank, GV, others | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more.
Relay Therapeutics, a biotechnology startup that’s meshing computational power with the latest experimental techniques around “protein ... |
| 20.12.2018 | Term Sheet — Thursday, December 20 | 5 Qs WITH A DEALMAKER
Earlier this month, French President Emmanuel Macron invited a contingent of 40 U.S.-based venture capitalists and limited partners to come talk tech.
Paid Content Securing the enterprise without boundaries From ExtraH... |
| 20.12.2018 | Relay Therapeutics Secures $400 Million in Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced the successful completion of a $400 million Series C financing.
Relay Therapeutics combines ... |
| 20.12.2018 | Relay Therapeutics Secures $400M in Series C Financing | Relay Therapeutics, a Cambridge, Mass.-based company working at the intersection of computation and biotechnology, completed a $400m Series C financing.
The round was led by the SoftBank Vision Fund with participation from new investors For... |
| 20.12.2018 | Relay Therapeutics raises $400 million in venture capital funding | Relay Therapeutics is expected to announce Thursday that it has raised $400 million in venture capital — one of the largest hauls this year by a privately held Massachusetts biotech — to advance its drug development programs.
The Cambridge,... |
| 02.04.2018 | Boston Startups and Tech Companies Hiring in April | April is the month to haul the grill out of the basement and also to dust off that musty resume. Boston tech and startup companies are hiring across the gamut if you feel like trying something new. Finish that Fenway Frank, wipe the mustard... |
| 15.12.2017 | Term Sheet — Friday, December 15 | THE CRYSTAL BALL
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
To my great dismay, no one made a prediction about when we’ll be driving our Teslas on Mars, but there were still some really ... |
| 14.12.2017 | Relay Therapeutics Raises $63M Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the successful completion of a $63 million Series B financin... |
| 14.12.2017 | Relay Therapeutics Completes $63M Series B Financing | Relay Therapeutics, a Cambridge, Mass.-based biotech company dedicated to developing medicines by leveraging insights from protein motion, completed a $63m Series B financing.
The round was led by BVF Partners, with participation from new i... |
| 14.12.2017 | Relay Therapeutics Raises $63M Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the successful completion of a $63 million Series B financin... |
| 14.12.2017 | Relay Therapeutics Secures $63 Million in Series B Financing | Proceeds to Support Advancement of Pipeline of Oncology Candidate Therapies and Further Development of Integrated Protein Motion-Based Platform
CAMBRIDGE, Mass.–(BUSINESS WIRE)–December 14, 2017–
Relay Therapeutics, a biotech company dedica... |
| 14.12.2017 | Relay Therapeutics Nabs $63M |
CAMBRIDGE, MA, Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the successful completion of a $63 million Series B financing.
>> Click... |
| 14.12.2016 | Third Rock invests $55M in ‘kidney renaissance’ startup | As a result of that close nurturing, Third Rock partner and interim Goldfinch CEO Abbie Celniker said the firm was comfortable raising the full $55 million itself, tapping into the last of its third venture fund.
The firm also has a lot of ... |
| 16.09.2016 | Protein-motion startup launches armed with $57M to develop drugs, crack cancer code | Molecular-level movies may not spark the imagination of too many directors. But for oncology patients, the imaging techniques Relay is working on represent another front in the effort to crack the code of cancer.
The technique that Relay, b... |
| 15.09.2016 | Relay Therapeutics Raises $57M in Series A Financing | Relay Therapeutics, a Cambridge, Massachusetts-based newly formed drug discovery company, raised $57m in Series A financing.
The round was led by founding investors Third Rock Ventures, with participation from an affiliate of D. E. Shaw Res... |
| 14.09.2016 | Third Rock Ventures Launches Relay Therapeutics with $57 Million Series A Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Third Rock Ventures, LLC today announced the formation of Relay Therapeutics with $57 million in Series A financing, including participation from an affiliate of D. E. Shaw Research, LLC. Relay Therapeutic... |
| 14.09.2016 | Relay Therapeutics Launches with $57M Series A |
CAMBRIDGE, MA, Third Rock Ventures, LLC today announced the formation of Relay Therapeutics with $57 million in Series A financing.
>> Click here for more funding data on Relay Therapeutics
>> To export Relay Therapeutics fu... |
| - | Protein-motion startup launches armed with $57M to develop drugs, crack cancer code | A picture may be worth a thousand words, but when it comes to disease discovery, Bay Area VC firm Third Rock Ventures is betting its money on moving pictures.
But instead of Hollywood blockbusters, the San Francisco-based investment firm in... |
| - | Protein motion-focused Relay Therapeutics files for $200M IPO | A company that less than two years ago raised $400 million in a venture capital funding round has filed to go public.
In a Securities and Exchange Commission filing on Wednesday, Cambridge, Massachusetts-based Relay Therapeutics said it wou... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.
Here are the 23 companie... |
| - | Relay Therapeutics hits VC jackpot with $400M Series C round for protein motion drug discovery | A discovery-stage biopharma startup focused on protein motion in drug discovery has raised a round of financing more than six times as big as the last one.
Relay Therapeutics, based in Cambridge, Massachusettts, said Thursday that it closed... |
| - | Third Rock invests $55M in ‘kidney renaissance’ startup | Third Rock Ventures has rallied a $55 million Series A to launch Goldfinch Bio, a startup that aims to apply precision medicine to kidney disease by combining biology and genetics.
Like all Third Rock companies, it seemed to appear out of n... |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Relay Therapeutics prices IPO at $400M | A company focused on discovering drugs through research into protein motion has announced the pricing of its initial public offering.
Cambridge, Massachusetts-based Relay Therapeutics said Wednesday that it had priced its IPO at $400 millio... |
